Iron laden macrophages in idiopathic pulmonary fibrosis: The telltale of occult alveolar hemorrhage?

Pulmonary Pharmacology and Therapeutics

Volumn 28, Issue 1, 2014, Pages 35-40

  Puxeddu, Ermanno ^a   Comandini, Alessia ^a   Cavalli, Francesco ^a   Pezzuto, Gabriella ^a   D'Ambrosio, Claudio ^a   Senis, Lucia ^a   Paci, Maurizio ^b   Curradi, Giacomo ^c   Sergiacomi, Gian Luigi ^a   Saltini, Cesare ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bronchoalveolar lavage; Hemosiderin and disease severity; Idiopathic pulmonary fibrosis; Total iron

Indexed keywords

HEMOSIDERIN; IRON;

AGED; ARTICLE; CARDIOPULMONARY FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EPITHELIUM; FEMALE; HEART CATHETERIZATION; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG ARTERY PRESSURE; LUNG HEMORRHAGE; LUNG LAVAGE; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SMOKING; SPECTROPHOTOMETRY; SYSTOLIC BLOOD PRESSURE; ADULT; CASE CONTROL STUDY; FIBROSING ALVEOLITIS; HEMORRHAGE; LUNG ALVEOLUS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HEMORRHAGE; HEMOSIDERIN; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IRON; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; PULMONARY ALVEOLI; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SMOKING; SPECTROPHOTOMETRY;

EID: 84900533687     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.12.002     Document Type: Article

References (59)

1. Azuma A., Nukiwa T., Tsuboi E., Suga M., Abe S., Nakata K., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2005, 171:1040-1047.
2. Bargagli E., Olivieri C., Bennett D., Prasse A., Muller-Quernheim J., Rottoli P. Oxidative stress in the pathogenesis of diffuse lung diseases: a review. Respir Med 2009, 103:1245-1256.
3. Baumgartner K.B., Samet J.M., Stidley C.A., Colby T.V., Waldron J.A. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997, 155:242-248.
4. Borok Z., Buhl R., Grimes G.J., Bokser A.D., Hubbard R.C., Holroyd K.J., et al. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991, 338:215-216.
5. Cantin A.M., North S.L., Fells G.A., Hubbard R.C., Crystal R.G. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987, 79:1665-1673.
6. Colombat M., Mal H., Groussard O., Capron F., Thabut G., Jebrak G., et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 2007, 38:60-65.
7. Demedts M., Behr J., Buhl R., Costabel U., Dekhuijzen R., Jansen H.M., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2229-2242. IFIGENIA Study Group.
8. Doll R., Peto R., Boreham J., Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004, 328:1519.
9. Ebina M., Shimizukawa M., Shibata N., Kimura Y., Suzuki T., Endo M., et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004, 169:1203-1208.
10. Epstein C.E., Elidemir O., Colasurdo G.N., Fan L.L. Time course of hemosiderin production by alveolar macrophages in a murine model. Chest 2001, 120:2013-2020.
11. Ghio A.J., Jaskot R.H., Hatch G.E. Lung injury after silica instillation is associated with an accumulation of iron in rats. Am J Physiol 1994, 267:L686-L692.
12. Ghio A.J., Richards J.H., Dittrich K.L., Samet J.M. Metal storage and transport proteins increase after exposure of the rat lung to an air pollution particle. Toxicol Pathol 1998, 26:388-394.
13. Ghio A.J., Stonehuerner J., Quigley D.R. Humic-like substances in cigarette smoke condensate and lung tissue of smokers. Am J Physiol 1994, 266:L382-L388.
14. Golde D.W., Drew W.L., Klein H.Z., Finley T.N., Cline M.J. Occult pulmonary haemorrhage in leukaemia. Br Med J 1975, 2:166-168.
15. Hilberg F., Roth G.J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68:4774-4782.
16. Hubbard R., Cooper M., Antoniak M., Venn A., Khan S., Johnston I., et al. Risk of cryptogenic fibrosing alveolitis in metal workers. Lancet 2000, 355:466-467.
17. Iwai K., Mori T., Yamada N., Yamaguchi M., Hosoda Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med 1994, 150:670-675.
18. Joppa P., Petrasova D., Stancak B., Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006, 130:326-333.
19. Kamp D.W., Israbian V.A., Yeldandi A.V., Panos R.J., Graceffa P., Weitzman S.A. Phytic acid, an iron chelator, attenuates pulmonary inflammation and fibrosis in rats after intratracheal instillation of asbestos. Toxicol Pathol 1995, 23:689-695.
20. Kawabata Y., Hoshi E., Murai K., Ikeya T., Takahashi N., Saitou Y., et al. Smoking-related changes in the background lung of specimens resected for lung cancer: a semiquantitative study with correlation to postoperative course. Histopathology 2008, 53:707-714.
21. Kim K.-H., Maldonado F., Ryu J.H., Eiken P.W., Hartman T.E., Bartholmai B.J., et al. Iron deposition and increased alveolar septal capillary density in nonfibrotic lung tissue are associated with pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Res 2010, 11:37.
22. King T.E., Behr J., Brown K.K., du Bois R.M., Lancaster L., de Andrade J.A., et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177:75-81.
23. King T.E., Brown K.K., Raghu G., du Bois R.M., Lynch D.A., Martinez F., et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011, 184:92-99.
24. LaLonde C., Ikegami K., Demling R. Aerosolized deferoxamine prevents lung and systemic injury caused by smoke inhalation. J Appl Physiol Bethesda Md 1994, 1985(77):2057-2064.
25. Lantuéjoul S., Sheppard M.N., Corrin B., Burke M.M., Nicholson A.G. Pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: a clinicopathologic study of 35 cases. Am J Surg Pathol 2006, 30:850-857.
26. Ley B., Ryerson C.J., Vittinghoff E., Ryu J.H., Tomassetti S., Lee J.S., et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012, 156:684-691.
27. Macintyre N., Crapo R.O., Viegi G., Johnson D.C., van der Grinten C.P.M., Brusasco V., et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J Off J Eur Soc Clin Respir Physiol 2005, 26:720-735.
28. Magro C.M., Waldman W.J., Knight D.A., Allen J.N., Nadasdy T., Frambach G.E., et al. Idiopathic pulmonary fibrosis related to endothelial injury and antiendothelial cell antibodies. Hum Immunol 2006, 67:284-297.
29. Maldonado F., Parambil J.G., Yi E.S., Decker P.A., Ryu J.H. Haemosiderin-laden macrophages in the bronchoalveolar lavage fluid of patients with diffuse alveolar damage. Eur Respir J Off J Eur Soc Clin Respir Physiol 2009, 33:1361-1366.
30. McGowan S.E., Henley S.A. Iron and ferritin contents and distribution in human alveolar macrophages. J Lab Clin Med 1988, 111:611-617.
31. McLaughlin R.F., Tueller E.E. Anatomic and histologic changes of early emphysema. Chest 1971, 59:592-599.
32. Meyer A., Buhl R., Kampf S., Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 1995, 152:1055-1060.
33. Meyer K.C., Raghu G., Baughman R.P., Brown K.K., Costabel U., du Bois R.M., et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012, 185:1004-1014.
34. Möller W., Barth W., Kohlhäufl M., Häussinger K., Stahlhofen W., Heyder J. Human alveolar long-term clearance of ferromagnetic iron oxide microparticles in healthy and diseased subjects. Exp Lung Res 2001, 27:547-568.
35. Montani D., Achouh L., Dorfmüller P., Le Pavec J., Sztrymf B., Tchérakian C., et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008, 87:220-233.
36. Montani D., Price L.C., Dorfmuller P., Achouh L., Jaïs X., Yaïci A., et al. Pulmonary veno-occlusive disease. Eur Respir J 2009, 33:189-200.
37. Nathan S.D., Shlobin O.A., Ahmad S., Koch J., Barnett S.D., Ad N., et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respir Int Rev Thorac Dis 2008, 76:288-294.
38. Nathan S.D., Shlobin O.A., Barnett S.D., Saggar Rajeev, Belperio J.A., Ross D.J., et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008, 102:1305-1310.
39. Nelson M.E., O'Brien-Ladner A.R., Wesselius L.J. Regional variation in iron and iron-binding proteins within the lungs of smokers. Am J Respir Crit Care Med 1996, 153:1353-1358.
40. Noble P.W., Albera C., Bradford W.Z., Costabel U., Glassberg M.K., Kardatzke D., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377:1760-1769.
41. Olakanmi O., McGowan S.E., Hayek M.B., Britigan B.E. Iron sequestration by macrophages decreases the potential for extracellular hydroxyl radical formation. J Clin Invest 1993, 91:889-899.
42. Pinho R.A., Silveira P.C.L., Silva L.A., Luiz Streck E., Dal-Pizzol F., Moreira F., et al. N-acetylcysteine and deferoxamine reduce pulmonary oxidative stress and inflammation in rats after coal dust exposure. Environ Res 2005, 99:355-360.
43. Rabiller A., Jaïs X., Hamid A., Resten A., Parent F., Haque R., et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006, 27:108-113.
44. Rad A.M., Janic B., Iskander A.S.M., Soltanian-Zadeh H., Arbab A.S. Measurement of quantity of iron in magnetically labeled cells: comparison among different UV/VIS spectrometric methods. BioTechniques 2007, 43:627-628. 630, 632 passim.
45. Raghu G., Behr J., Brown K.K., Egan J.J., Kawut S.M., Flaherty K.R., et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med 2013, 158:641-649. ARTEMIS-IPF Investigators*.
46. Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183:788-824.
47. Rennard S.I., Basset G., Lecossier D., O'Donnell K.M., Pinkston P., Martin P.G., et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol Bethesda Md 1986, 1985(60):532-538.
48. Renzoni E.A., Walsh D.A., Salmon M., Wells A.U., Sestini P., Nicholson A.G., et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003, 167:438-443.
49. Richeldi L., Costabel U., Selman M., Kim D.S., Hansell D.M., Nicholson A.G., et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011, 365:1079-1087.
50. Robinson K., Conroy R.M., Mulcahy R. When does the risk of acute coronary heart disease in ex-smokers fall to that in non-smokers? A retrospective study of patients admitted to hospital with a first episode of myocardial infarction or unstable angina. Br Heart J 1989, 62:16-19.
51. Salazar-Montes A., Ruiz-Corro L., López-Reyes A., Castrejón-Gómez E., Armendáriz-Borunda J. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur J Pharmacol 2008, 595:69-77.
52. Salih Z.N., Akhter A., Akhter J. Specificity and sensitivity of hemosiderin-laden macrophages in routine bronchoalveolar lavage in children. Arch Pathol Lab Med 2006, 130:1684-1686.
53. Saltini C., Hance A.J., Ferrans V.J., Basset F., Bitterman P.B., Crystal R.G. Accurate quantification of cells recovered by bronchoalveolar lavage. Am Rev Respir Dis 1984, 130:650-658.
54. Samara K.D., Margaritopoulos G., Wells A.U., Siafakas N.M., Antoniou K.M. Smoking and pulmonary fibrosis: novel insights. Pulm Med 2011, 2011:461439.
55. Sherman J.M., Winnie G., Thomassen M.J., Abdul-Karim F.W., Boat T.F. Time course of hemosiderin production and clearance by human pulmonary macrophages. Chest 1984, 86:409-411.
56. Steele M.P., Speer M.C., Loyd J.E., Brown K.K., Herron A., Slifer S.H., et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005, 172:1146-1152.
57. Taylor H.E., Strong G.F. Pulmonary hemosiderosis in mitral stenosis. Ann Intern Med 1955, 42:26-35.
58. Thompson A.B., Bohling T., Heires A., Linder J., Rennard S.I. Lower respiratory tract iron burden is increased in association with cigarette smoking. J Lab Clin Med 1991, 117:493-499.
59. Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 1963, 18:225-237.